 Coramsine

Coramsine (SBP002) was an experimental cancer drug that was evaluated in preliminary clinical trials, but was abandoned by Solbec Pharmaceuticals Ltd after the results were insufficient for them to raise investment capital to continue its development.Coramsine is a chemotherapeutic and immunomodulating agent whose primary ingredients are two solasodine glycoalkaloids, solasonine and solamargine, which are derived from the plant "Solanum linnaeanum" (Devil's Apple).